-
- A Hadj Tahar.
- Issues Emerg Health Technol. 2004 Jun 1 (58): 1-4.
AbstractIn the US, subcutaneous administration of omalizumab is indicated for adults and adolescents (age greater than or equal to 12 years) with allergic asthma that is moderate to severe and inadequately controlled with inhaled corticosteroids. In placebo-controlled trials, omalizumab reduces asthma exacerbations and the need for inhaled steroids in this group. The value of omalizumab to patients with severe asthma (e.g., refractory asthma) has yet to be proven. Data are lacking on the efficacy of omalizumab compared to add-on therapies such as inhaled long-acting beta-2 agonists or anti-leukotriene agents. Further evaluation on omalizumab needs to be done in the pediatric population.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..